FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4

BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem ce...

Descripción completa

Detalles Bibliográficos
Autores principales: McClements, Lana, Annett, Stephanie, Yakkundi, Anita, O’Rourke, Martin, Valentine, Andrea, Moustafa, Nermeen, Alqudah, Abdelrahim, Simões, Bruno M., Furlong, Fiona, Short, Amy, McIntosh, Stuart A., McCarthy, Helen O., Clarke, Robert B., Robson, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460676/
https://www.ncbi.nlm.nih.gov/pubmed/30975104
http://dx.doi.org/10.1186/s12885-019-5500-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460676/
https://www.ncbi.nlm.nih.gov/pubmed/30975104
http://dx.doi.org/10.1186/s12885-019-5500-0

Ejemplares similares